Literature DB >> 20855644

The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas.

Anthony Rhodes1, Julia Sarson, Emma E Assam, Sarah J R Dean, Edward C Cribb, Andrew Parker.   

Abstract

The reliability of the rabbit monoclonal antibodies SP1, SP2, SP3, and 4B5 was immunohistochemically assessed on a range of 96 invasive breast carcinomas and the results compared with those achieved with established antibody markers for estrogen receptors (6F11), progesterone receptors (PgR636), and HER2 (polyclonal A0485 and clone CB11), with HER2 status validated by fluorescence in situ hybridization (FISH) and silver in situ hybridization. Optimal results depended on the duration of microwave antigen-retrieval time and the use of a high pH buffer for rabbit and mouse estrogen receptor antibodies (SP1 and 6F11), although only on antigen-retrieval duration for the progesterone receptors SP2 and PgR636. The highest rate of concordance between HER2 overexpression and HER2 gene amplification was with the rabbit monoclonal antibodies (SP3 and 4B5) and FISH. Rabbit monoclonal antibodies are reliable alternatives to established antibody markers for the immunohistochemical testing of estrogen receptors, progesterone receptors, and HER2 in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20855644     DOI: 10.1309/AJCPOG3O3KTPZQNK

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  6 in total

1.  The Importance of Epitope Density in Selecting a Sensitive Positive IHC Control.

Authors:  Kodela Vani; Seshi R Sompuram; Anika K Schaedle; Anuradha Balasubramanian; Monika Pilichowska; Stephen Naber; Jeffrey D Goldsmith; Kueikwun G Chang; Farzad Noubary; Steven A Bogen
Journal:  J Histochem Cytochem       Date:  2017-06-30       Impact factor: 2.479

2.  Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.

Authors:  Daniel E Carvajal-Hausdorf; Kurt A Schalper; Lajos Pusztai; Amanda Psyrri; Konstantine T Kalogeras; Vasiliki Kotoula; George Fountzilas; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2015-05-19       Impact factor: 13.506

3.  Analytic Response Curves of Clinical Breast Cancer IHC Tests.

Authors:  Kodela Vani; Seshi R Sompuram; Anika K Schaedle; Anuradha Balasubramanian; Steven A Bogen
Journal:  J Histochem Cytochem       Date:  2017-01-01       Impact factor: 2.479

4.  Evaluation of the progesterone receptor status in breast cancer using three different antibodies: a comparison by Allred score system.

Authors:  Renata Dalmaschio Daltoé; Klesia Pirola Madeira; Alex Assis de Carvalho; Lucas Cunha Dias de Rezende; Ian Victor Silva; Leticia Batista Azevedo Rangel
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

5.  Risk of contralateral second primary breast cancer according to hormone receptor status in Germany.

Authors:  Carsten Rusner; Katharina Wolf; Ulrike Bandemer-Greulich; Jutta Engel; Christa Stegmaier; Bernd Holleczek; Gabriele Schubert-Fritschle; Anett Tillack; Andreas Stang
Journal:  Breast Cancer Res       Date:  2014-10-03       Impact factor: 6.466

6.  Immunohistochemical Performance of Estrogen and Progesterone Receptor Antibodies on the Dako Omnis Staining Platform: Evaluation in Multicenter Studies.

Authors:  David Hicks; Patrizia Dell'Orto; Mary Falzon; Kirsten D Hoff; Yaron Y Levy; Loralee McMahon; Keith Miller; Leila Russo; Giuseppe Viale
Journal:  Appl Immunohistochem Mol Morphol       Date:  2017 May/Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.